Eisai Co., Ltd. (ESAIY)
| Previous Close | 8.64 |
| Open | 8.60 |
| Bid | 8.49 x 40000 |
| Ask | 8.51 x 40000 |
| Day's Range | 8.49 - 8.60 |
| 52 Week Range | 8.42 - 13.99 |
| Volume | |
| Avg. Volume | 158,498 |
| Market Cap | 9.748B |
| Beta (5Y Monthly) | -0.08 |
| PE Ratio (TTM) | 44.68 |
| EPS (TTM) | 0.19 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | 0.26 (3.02%) |
| Ex-Dividend Date | Mar 27, 2024 |
| 1y Target Est | N/A |
PR NewswireEISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY
Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT06462404. Study sites are also planned for Canada.
PR NewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. L
